Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
The endogenous cannabinoid anandamide is removed from the synaptic space by a high-affinity transport system present in neurons and astrocytes, which is inhibited by N -(4-hydroxyphenyl)-arachidonamide (AM404). After internalization, anandamide is hydrolyzed by fatty-acid amide hydrolase (FAAH), an intracellular membrane-bound enzyme that also cleaves AM404. Based on kinetic evidence, it has recently been suggested that anandamide internalization may be mediated by passive diffusion driven by FAAH activity. To test this possibility, in the present study, we have investigated anandamide internalization in wild-type and FAAH-deficient (FAAH –/– ) mice. Cortical neurons from either mouse strain internalized [ 3 H]anandamide through a similar mechanism, i.e., via a rapid temperature-sensitive and saturable process, which was blocked by AM404. Moreover, systemic administration of AM404 to either wild-type or FAAH –/– mice enhanced the hypothermic effects of exogenous anandamide, a response that was prevented by the CB 1 cannabinoid antagonist rimonabant (SR141716A). The results indicate that anandamide internalization in mouse brain neurons is independent of FAAH activity. In further support of this conclusion, the compound N -(5Z, 8Z, 11Z, 14Z eicosatetraenyl)-4-hydroxybenzamide (AM1172) blocked [ 3 H]anandamide internalization in rodent cortical neurons and human astrocytoma cells without acting as a FAAH substrate or inhibitor. AM1172 may serve as a prototype for novel anandamide transport inhibitors with increased metabolic stability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Self-citationFunctional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Self-citationBrewer, G. J. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490420510 · Cited by 541
Research works printed but not linked: 2
- Masson, J., Sagne, C., Hamon, M. & El Mestikawy, S. (1999) Pharmacol. Rev. 51, 439–464.10471414
- Ligresti A. Morera E. Van Der Stelt M. M. Monory K. Lutz B. Ortar G. & Di Marzo V. (2004) Biochem. J. in press.
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Studies with cells isolated from FAAH+/+ and FAAH−/− mice did not resolve this issue, as the absence of FAAH was found not to affect anandamide uptake (Fegley et al., 2004) or to reduce it substantially (Ortega-Gutierrez et al., 2004), albeit under different experimental conditions.”
BackgroundEndocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
“AM404 is a potent activator of vanilloid subtype 1 receptors (TRPV1) (235), and an inhibitor of the cellular anandamide uptake (anandamide membrane transporter, AMT), which leads to increased levels of endogenous cannabinoids (19,66,82,210,235) [evidence for partially overlapping ligand recognition properties of TRPV1…”
BackgroundEnzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
“…the endocannabinoids is performed by a two-step process consisting of carrier-mediated internalization (Beltramo et al., 1997; Hillard et al., 1997; Fegley et al., 2004), followed by intracellular hydrolysis catalyzed by fatty-acid amide hydrolase and monoacylglycerol lipase (MGL) for anandamide…”
MethodSelf-citationHögestätt, E. D., Jönsson, B. A. G., Ermund, A., Andersson, D. A., Björk, H., Alexander, J. P., Cravatt, B. F., Basbaum, A. I., & Zygmunt, P. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501489200 · Cited by 454
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
“After release from cells, polyunsaturated FAEs such as anandamide may be eliminated via a two-step process consisting of high-affinity transport into cells (Di Marzo et al., 1994; Beltramo et al., 1997; Hillard et al., 1997; Fegley et al., 2004; Ortega-Gutierrez et al., 2004) followed by intracellular degradation, cat…”
BackgroundSelf-citationTHE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407
“However, a recent report seems to confirm that transport and degradation are independent processes (Fegley et al., 2004).”
BackgroundBiochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Di Marzo, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 383
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
“AM404 and other inhibitors of the anandamide transporter, such as the newly identified AM1172 (Fegley et al, 2004), may enhance the process of extinction through an alternate mechanism.”
BackgroundThe Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Self-citationChemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327
“Additionally, its relatively short half-life in vivo (Fegley et al., 2004; Lichtman et al., 2004) has limited its use in certain paradigms, including chronic dosing studies.”
BackgroundIdentification of intracellular carriers for the endocannabinoid anandamide
Kaczocha, M., Glaser, S. T., & Deutsch, D. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901515106 · Cited by 326
“Although many of these structural analogs of AEA reduce its uptake by inhibiting FAAH (11, 12, 58, 59), several compounds have recently been described that do not appreciably inhibit this enzyme (60, 61).”
BackgroundEndocannabinoids: synthesis and degradation
Di Marzo, V. (2006) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/112_0505 · Cited by 311
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 263
“The pharmacological profile of CBD somewhat resembles that of AM404, a synthetic drug known to inhibit anandamide uptake/metabolism (Beltramo et al., 1997; De Petrocellis et al., 2000; Fegley et al., 2004; Fowler et al., 2004; Jarrahian et al., 2000) and to activate TRPV1 receptors (De Petrocellis et al.”
BackgroundThe endocannabinoid system in brain reward processes
Solinas, M., Goldberg, S. R., & Piomelli, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.130 · Cited by 244
“cannabinoid levels, CB-like effects, and enhanced and prolonged effects of exogenously administered endocannabinoids (Piomelli et al., 1999; De Petrocellis et al., 2000; Lopez-Rodriguez et al., 2003; Fegley et al., 2004; Glaser et al., 2005).”
BackgroundInfluentialSelf-citationLeweke, F. M., Giuffrida, A., Koethe, D., Schreiber, D., Nolden, B. M., Kranaster, L., Neatby, M. A., Schneider, M., Gerth, C. W., Hellmich, M., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.04.025 · Cited by 240
“The possibility that endogenous anandamide may act as a downstream signal regulating dopaminergic transmission is further supported by animal experiments showing that the anandamide reuptake inhibitor AM404 attenuates certain behavioral effects exerted by D2-type receptor agonists, such as motor hyperactivity, whereas…”
ResultSelf-citationPresynaptic Modulation by Endocannabinoids
Lovinger, D. M. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74805-2_14 · Cited by 246
“2-AG can be disrupted by various agents that appear to act independently of other EC-interacting proteins (Hillard and Jarrahian 2000; Fegley et al. 2004; Moore et al. 2005).”
BackgroundPotential Analgesic Mechanisms of Acetaminophen
Smith, H. (2009) · Pain Physician · doi:10.36076/ppj.2009/12/269 · Cited by 245
Integration of Endocannabinoid and Leptin Signaling in an Appetite-Related Neural Circuit
Jo, Y.-H., Chen, Y.-J. J., Chua, S. C., Talmage, D. A., & Role, L. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.021 · Cited by 234
Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404
Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G. L., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301061 · Cited by 231
“Indeed, the compound AM1172 (Fegley et al, 2004) also acts as a direct partial agonist of CB1 receptors, while other agents, such as VDM11, have been shown to interact with multiple targets (Kelley and Thayer, 2004).”
BackgroundMethodInfluentialSelf-citationParacetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223
“(2005) AM404 was shown to have analgesic properties mediated through the inhibition of endocannabinoid reuptake, thereby by preventing the reuptake of anandamide from the synaptic cleft [91].”
BackgroundThe endocannabinoid signalling system: Biochemical aspects
BISOGNO, T., LIGRESTI, A., & DIMARZO, V (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.027 · Cited by 201
“It can also inhibit FAAH, presumably by acting as an alternative substrate (Fegley et al., 2004), and activate vanilloid TRPV1 receptors (Jarrahian et al.”
BackgroundInfluentialLutz, B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.007 · Cited by 192
Kaczocha, M., Vivieca, S., Sun, J., Glaser, S. T., & Deutsch, D. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304907 · Cited by 187
“The prototypical transport inhibitors, OMDM1, OMDM2, VDM11, AM1172, and AM404 (12, 14, 15, 28), which reduce AEA uptake across multiple cell types, were employed.”
MethodInfluentialHamilton, J. A., Hillard, C. J., Spector, A. A., & Watkins, P. A. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0060-1 · Cited by 179
“However, this is not the case for neuronal uptake, as it occurs even in neurons prepared from mice null for FA amide hydrolase (Fegley et al. 2004).”
BackgroundParacetamol – An old drug with new mechanisms of action
Przybyła, G. W., Szychowski, K. A., & Gmiński, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13392 · Cited by 190
The endocannabinoid system as a target for the treatment of neurodegenerative disease
Scotter, E. L., Abood, M. E., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00735.x · Cited by 179
“…Journal of Pharmacology (2010) 160 480–498 Fowler, 2005; Alexander and Cravatt, 2006; Kaczocha et al., 2006), but not all (Ortar et al., 2003; Fegley et al., 2004), of these uptake inhibitors have subsequently been shown to inhibit FAAH, which would reduce the concentration gradient for…”
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Self-citationTransport of endocannabinoids across the plasma membrane and within the cell
Fowler, C. J. (2013) · The FEBS Journal · doi:10.1111/febs.12212 · Cited by 168
Endogenous Cannabinoids: Structure and Metabolism
Bisogno, T. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01676.x · Cited by 164
Identification of a high-affinity binding site involved in the transport of endocannabinoids
Moore, S. A., Nomikos, G. G., Dickason-Chesterfield, A. K., Schober, D. A., Schaus, J. M., Ying, B.-P., Xu, Y.-C., Phebus, L., Simmons, R. M. A., Li, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507470102 · Cited by 165
TRPV1 in Brain Is Involved in Acetaminophen-Induced Antinociception
Mallet, C., Barrière, D. A., Ermund, A., Jönsson, B. A. G., Eschalier, A., Zygmunt, P. M., & Högestätt, E. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012748 · Cited by 165
“The second phase of the formalin test was not affected by this dose of AM404, possibly due to a rapid elimination of AM404 in the brain in the absence of its precursor p-aminophenol [12,26].”
BackgroundMarinelli, S., Marzo, V. D., Florenzano, F., Fezza, F., Viscomi, M. T., van der Stelt, M., Bernardi, G., Molinari, M., Maccarrone, M., & Mercuri, N. B. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301118 · Cited by 170
“Being an endogenous chemical signal, NADA signaling can be regulated by acting on both its membrane transport system and metabolism (Di Marzo et al, 1994; Beltramo et al, 1997; Cravatt et al, 2001; Fegley et al, 2004).”
BackgroundPlasma anandamide concentrations are lower in children with autism spectrum disorder
Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018) · Molecular Autism · doi:10.1186/s13229-018-0203-y · Cited by 156
A role for cannabinoid CB1 receptors in mood and anxiety disorders
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00005 · Cited by 156
“Although the molecular entity responsible for endocannabinoid reuptake still remains unknown, pharmacological ligands that specifically inhibit this process have been identified (Beltramo et al., 1997; De Petrocellis et al., 2000; Fegley et al., 2004).”
BackgroundPalmitoylethanolamide in CNS health and disease
Raso, G. M., Russo, R., Calignano, A., & Meli, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.05.006 · Cited by 165
“[69] Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al.”
BackgroundEndocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
Jhaveri, M. D., Richardson, D., & Chapman, V (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707433 · Cited by 144
“In addition, both AEA and 2AG are believed to be transported into cells (Day et al., 2001; Fegley et al., 2004; Ligresti et al., 2004; Ortega-Gutierrez et al., 2004; McFarland and Barker, 2004; Hillard and Jarrahian, 2005; Hermann et al., 2006), which also contributes to the termination of the biological activity of E…”
BackgroundAlexander, J. P., & Cravatt, B. F. (2006) · Journal of the American Chemical Society · doi:10.1021/ja062999h · Cited by 140
Anandamide transport: A critical review
Glaser, S. T., Kaczocha, M., & Deutsch, D. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.007 · Cited by 160
Molecular Identification of Albumin and Hsp70 as Cytosolic Anandamide-Binding Proteins
Oddi, S., Fezza, F., Pasquariello, N., D'Agostino, A., Catanzaro, G., Simone, C. D., Rapino, C., Finazzi‐Agrò, A., & Maccarrone, M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.004 · Cited by 156
Endocannabinoid Transport Revisited
Nicolussi, S., & Gertsch, J. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2014.12.011 · Cited by 141
More surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128
“Moreover, anandamide transport is clearly distinct from FAAH, since FAAH inhibitors do not interfere with its activity (Beltramo et al., 1997; Fegley et al., 2004).”
Self-citationRegulation of Gonadotropin-Releasing Hormone Secretion by Cannabinoids
Gammon, C. M., Freeman, G. M., Xie, W., Petersen, S. L., & Wetsel, W. C. (2005) · Endocrinology · doi:10.1210/en.2004-1672 · Cited by 126
Karanian, D. A., Brown, Q. B., Makriyannis, A., Kosten, T. A., & Bahr, B. A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2347-05.2005 · Cited by 125
“Inhibitors of the transport system have been shown to enhance the effects of exogenous cannabinoid ligands (Giuffrida et al., 2000; Fegley et al., 2004; Hájos et al., 2004).”
InfluentialSelf-citationEndocannabinoid signaling and food addiction
D’Addario, C., Bonaventura, M. V. M. D., Pucci, M., Romano, A., Gaetani, S., Ciccocioppo, R., Cifani, C., & Maccarrone, M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.008 · Cited by 134
“Still under debate is whether or not eCB transport and degradation are coupled or independent processes (Fegley et al., 2004).”
BackgroundThe role of endocannabinoids in pain modulation
Zogopoulos, P., Vasileiou, I., Patsouris, E., & Theocharis, S. E. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12008 · Cited by 126
Functional neuroanatomy of the endocannabinoid system
Pazos, M. R., NUNEZ, E., Benito, C., Tolón, R. M., & Romero, J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.030 · Cited by 132
“On the contrary, Fegley et al. (2004) have recently shown that this process is indeed non-dependent on FAAH activity in mouse brain neurons, while Ligresti et al. (2004) have demonstrated that at least one protein different from FAAH is needed for AEA transport through the cell membrane.”
BackgroundA synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development
Kim, H.-Y., Spector, A. A., & Xiong, Z.-M. (2011) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2011.07.002 · Cited by 104
Solinas, M., Tanda, G., Justinova, Z., Wertheim, C. E., Yasar, S., Piomelli, D., Vadivel, S. K., Makriyannis, A., & Goldberg, S. R. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114124 · Cited by 104
“, 2005), and administration of AM-404 at doses (5–10 mg/kg) similar to those used in the present experiments increases anandamide concentrations in plasma and some brain areas (Giuffrida et al., 2000; Fegley et al., 2004) and potentiates and prolongs many of physiological and behavioral effects of anandamide (Beltramo…”
BackgroundInfluentialSelf-citationSolinas, M., Panlilio, L. V., Tanda, G., Makriyannis, A., Matthews, S. A., & Goldberg, S. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300754 · Cited by 109
Self-citationHwang, J., Adamson, C. L., Butler, D., Janero, D. R., Makriyannis, A., & Bahr, B. A. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.003 · Cited by 110
Self-citationFatty Acid Amide Hydrolase: A Gate-Keeper of the Endocannabinoid System
Fezza, F., De Simone, C., Amadio, D., & Maccarrone, M. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_4 · Cited by 99
“, 2003); saturable AEA accumulation can be still observed in synaptosomes and cells prepared from FAAH-null mice (Ligresti et al., 2004; Fegley et al., 2004).”
BackgroundKaczocha, M., Hermann, A., Glaser, S. T., Bojesen, I. N., & Deutsch, D. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509721200 · Cited by 98
La Rana, G., Russo, R., Campolongo, P., Bortolato, M., Mangieri, R. A., Cuomo, V., Iacono, A., Raso, G. M., Meli, R., Piomelli, D., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100792 · Cited by 97
“This lack of effect might be accounted for by enzymatic degradation (Fegley et al., 2004).”
BackgroundInfluentialSelf-citationChemical probes to potently and selectively inhibit endocannabinoid cellular reuptake
Chicca, A., Nicolussi, S., Bartholomäus, R., Blunder, M., Aparisi Rey, A., Petrucci, V., Reynoso-Moreno, I. D. C., Viveros-Paredes, J. M., Dalghi Gens, M., Lutz, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704065114 · Cited by 96
Deutsch, D. G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00370 · Cited by 106
“FAAH removes AEA from inside the cell, disrupting the equilibrium between inside and outside the cell, generating a concentration gradient that drives uptake (Figure 2).”
Godlewski, G., Alapafuja, S. O., Bátkai, S., Nikas, S. P., Cinar, R., Offertáler, L., Osei-Hyiaman, D., Liu, J., Mukhopadhyay, B., Harvey-White, J., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.013 · Cited by 95
“The effect of AM3506 on anandamide transport was assessed by measuring its ability to inhibit [(3)H]anandamide uptake by cultured CCF-STTG1 astrocytoma cells, as described (Fegley et al., 2004).”
Self-citationFatty Acid Amide Hydrolase Determines Anandamide-induced Cell Death in the Liver
Siegmund, S. V., Seki, E., Osawa, Y., Uchinami, H., Cravatt, B. F., & Schwabe, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509706200 · Cited by 94
Karanian, D. A., Karim, S. L., Wood, J. T., Williams, J. S., Lin, S., Makriyannis, A., & Bahr, B. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120147 · Cited by 98
“Enhancement of endocannabinoid responses can be achieved with disruption of FAAH activity (Cravatt et al., 2001; Kathuria et al., 2003), as well as through inhibition of the transporter (Giuffrida et al., 2000; Fegley et al., 2004; Karanian et al., 2005b).”
BackgroundSelf-citationTrezza, V., & Vanderschuren, L. J. M. J. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141069 · Cited by 91
“However, genetic deletion of FAAH does not affect anandamide uptake, which argues against this possibility (Fegley et al., 2004).”
BackgroundTambaro, S., & Bortolato, M. (2012) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 89
“Following release and activation of CB receptors, anandamide is rapidly removed from the synaptic cleft by a carrier-mediated system [69-72] and subsequently hydrolyzed by the membrane enzyme fatty acid amide hydrolase (FAAH) [73-75].”
BackgroundThe endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 92
“, 2003) and susceptible to stereoselective pharmacological inhibition (Fegley et al., 2004; Piomelli et al., 1999).”
BackgroundSelf-citationEndocannabinoids in cerebrovascular regulation
Benyó, Z., Ruisanchez, É., Leszl-Ishiguro, M., Sándor, P., & Pacher, P. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00571.2015 · Cited by 94
Fowler, C. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.001 · Cited by 100
Latest advances in cannabinoid receptor agonists
Thakur, G. A., Tichkule, R. B., Bajaj, S., & Makriyannis, A. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903436505 · Cited by 103
“The transport of these endocannabinoids into the cell is mediated through a putative transporter which remains to be cloned [30-34].”
BackgroundSelf-citationHaj-Dahmane, S., Shen, R.-Y., Elmes, M. W., Studholme, K., Kanjiya, M. P., Bogdan, D., Thanos, P. K., Miyauchi, J. T., Tsirka, S. E., Deutsch, D. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721339115 · Cited by 80
“This notion is based on the inhibition of eCB uptake by structural eCB analogs (39, 40) and the reduction of retrograde eCB signaling, which has been attributed to inhibition of eCB release (41, 42).”
BackgroundEndocannabinoid-Based Therapies
Piomelli, D., & Tagne, A. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-021800 · Cited by 86
Self-citationChapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
“Genetic deletion of the faah gene or pharmacological inhibition of FAAH activity impairs AEA hydrolysis, resulting in elevated brain levels of this lipid mediator (Cravatt et al., 2001; Fegley et al., 2004).”
BackgroundSelf-citationMicroglia produce and hydrolyze palmitoylethanolamide
Muccioli, G. G., & Stella, N. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.015 · Cited by 86
“While PEA is found in significant levels in whole mouse or rat brains (100-550 pmol/g) (Cravatt et al. 2004; Fegley et al. 2004; Franklin et al. 2003; Patel et al. 2005), pathophysiological stimuli may selectively increase its levels.”
BackgroundKlinger-Gratz, P. P., Ralvenius, W. T., Neumann, E., Kato, A., Nyilas, R., Lele, Z., Katona, I., & Zeilhofer, H. U. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1945-17.2017 · Cited by 74
“AM 404 increases tissue concentrations of the endocannabinoid arachidonoyl ethanolamide, also known as anandamide, through an inhibition of anandamide reuptake into neurons and astrocytes (Beltramo et al., 1997; Fegley et al., 2004).”
BackgroundStructural Requirements for Cannabinoid Receptor Probes
Thakur, G. A., Nikas, S. P., Li, C., & Makriyannis, A. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_7 · Cited by 85
Self-citationThe endocannabinoid signaling system: Pharmacological and therapeutic aspects
Fowler, C. J., Holt, S., Nilsson, O. R., Jonsson, K., Tiger, G., & Jacobsson, S. O. P. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.023 · Cited by 83
“uptake to a passive diffusion process driven to a varying extent by the AEA metabolising enzyme fatty acid amide hydrolase (FAAH) (Glaser et al., 2003; Hillard and Jarrahian, 2003; McFarland and Barker, 2004; see also Ronesi et al., 2004; Ligresti et al., 2004; Fegley et al., 2004; Ortega-Gutiérrez et al., 2004; McFar…”
InfluentialScherma, M., Justinová, Z., Zanettini, C., Panlilio, L. V., Mascia, P., Fadda, P., Fratta, W., Makriyannis, A., Vadivel, S. K., Gamaleddin, I., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01467.x · Cited by 77
“tration increases brain levels of AEA, but it does not significantly affect brain levels of OEA or PEA (Fegley et al., 2004; Bortolato et al., 2006).”
BackgroundInfluentialSelf-citationPotential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Galaj, E., & Xi, Z. (2019) · CNS Drugs · doi:10.1007/s40263-019-00664-w · Cited by 71
Ligresti, A., Cascio, M. G., Pryce, G., Kulasegram, S., Beletskaya, I., De Petrocellis, L., Saha, B., Mahadevan, A., Visintin, C., Wiley, J. L., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706418 · Cited by 65
“…and O-3262 exert little, if any, inhibition of AEA intracellular hydrolysis, which in RBL-2H3 cells is catalyzed by FAAH, confirm recent evidence (Fegley et al., 2004; Ligresti et al., 2004; OrtegaGutierrez et al., 2004) that this latter protein is not solely responsible for AEA cellular uptake,…”
BackgroundInfluentialCarbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation
Ortar, G., Cascio, M. G., Moriello, A. S., Camalli, M., Morera, E., Nalli, M., & Marzo, V. D. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.02.023 · Cited by 67
Makriyannis, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500220s · Cited by 68
Self-citationSaliba, S. W., Marcotegui, A. R., Fortwängler, E., Ditrich, J., Perazzo, J. C., Muñoz, E., de Oliveira, A. C. P., & Fiebich, B. L. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1014-3 · Cited by 62
“Furthermore, it has been shown that AM404 induces hypothermia [12, 13] and analgesia in animal models [14–16].”
Barrière, D. A., Mallet, C., Blomgren, A., Simonsen, C., Daulhac, L., Libert, F., Chapuy, E., Etienne, M., Högestätt, E. D., Zygmunt, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070690 · Cited by 62
“As shown previously, intracerebroventricular injection of AM404 can reproduce the TRPV1-dependent antinociceptive effect of oral paracetamol in the mouse formalin test [3], although the duration of action of AM404 was relatively short, probably reflecting rapid elimination of AM404 in the absence of its precursor 4-am…”
Alvarez‐Jaimes, L., Stouffer, D. G., & Parsons, L. H. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06301.x · Cited by 62
“Systemic AM404 administration increases AEA levels in rat plasma and bulk levels in tissue from some brain areas, with lesser increases in brain 2-AG levels (Beltramo et al. 1997; Beltramo and Piomelli 2000; Giuffrida et al. 2000; Fegley et al. 2004; Di et al. 2005; Bortolato et al. 2006).”
BackgroundSteiner, A. A., Molchanova, A. Y., Doğan, M. D., Patel, S., Pétervári, E., Balaskó, M., Wanner, S. P., Eales, J., de Oliveira, D. L., Gavva, N. R., et al. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.202465 · Cited by 74
“That peripheral administration of AEA causes hypothermia in rats and mice has been shown repeatedly (Crawley et al. 1993; Di Marzo et al. 2000; Fegley et al. 2004; Garami et al. 2011), including in our present study (Suppl.”
BackgroundPasquale, E. D., Chahinian, H., Sanchez, P., & Fantini, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004989 · Cited by 66
“Because the transport of anandamide is saturable and specifically inhibited by anandamide analogues that are not broken by FAAH, other authors argue for the existence of a proteic transporter for anandamide [30].”
BackgroundFiori, A., Bari, M., Granata, F., Gasperi, V., Stefano, M. E. D., Finazzi‐Agrò, A., Ström, R., & Maccarrone, M. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-06-0413 · Cited by 64
Role of the endogenous cannabinoid system in nicotine addiction: novel insights
Gamaleddin, I. H. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00041 · Cited by 58
Scala, C. D., Fantini, J., Yahi, N., Barrantes, F. J., & Chahinian, H. (2018) · Biomolecules · doi:10.3390/biom8020031 · Cited by 60
Mechanisms of endocannabinoid transport in the brain
Kaczocha, M., & Haj‐Dahmane, S. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15469 · Cited by 62
“…transporter is based largely upon the inhibition of endo- cannabinoid transport by structural analogues of endocannabinoids as well as its temperature-dependence (Beltramo et al., 1997; Chicca et al., 2012; Di Marzo et al., 1994; Fegley et al., 2004; Moore et al., 2005; Piomelli et al., 1999).”
BackgroundOddi, S., Bari, M., Battista, N., Barsacchi, D., Cozzani, I., & Maccarrone, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4446-8 · Cited by 62
Fowler, C. J. (2006) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00442.x · Cited by 57
Targeting the endocannabinoid system in treating brain disorders
Bahr, B. A., Karanian, D. A., Makanji, S. S., & Makriyannis, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.4.351 · Cited by 63
“The biological activity of anandamide is thought to be terminated by two processes; the first is the internalisation of anandamide through a highly selective carrier-mediated transport system [20-23].”
BackgroundSelf-citationSpradley, J. M., Guindon, J., & Hohmann, A. G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.007 · Cited by 54
“Endocannabinoid uptake inhibitors produce pharmacological effects in FAAH knockout mice, suggesting that endocannabinoid uptake is not dependent on FAAH [64].”
BackgroundBlocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus
Karanian, D. A., Brown, Q. B., Makriyannis, A., & Bahr, B. A. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.009 · Cited by 62
Self-citationBiosynthesis and Fate of Endocannabinoids
Cascio, M. G., & Marini, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_2 · Cited by 60
“2002) and (5) a saturable AEA accumulation was observed in synaptosomes and cells prepared from genetically modified mice that do not express FAAH (Fegley et al. 2004; Ligresti et al. 2004).”
BackgroundThe role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer's disease
Jain, S., Bisht, A., Verma, K., Negi, S., Paliwal, S., & Sharma, S. K. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3680 · Cited by 57
“N(4-hydroxyphenyl)-arachidonami (AM404) act as a FAAH inhibitor and suppresses anandamide behaviour physiologically.(72,73) Infusion of”
BackgroundHofmann, N., Barth, S., Waldeck‐Weiermair, M., Klec, C., Strunk, D., Malli, R., & Graier, W. F. (2014) · Biology Open · doi:10.1242/bio.20149571 · Cited by 59
“KEY WORDS: transient receptor potential vanilloid 1, TRPV1, anandamide, AEA, endothelial colony-forming cells, ECFC, anandamide transport, proliferation, network-formation, angiogenesis”
Background
Metadata
- Authors
- Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D.
- Affiliations
- University of Connecticut (US)
- Corresponding author
- Piomelli, D.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-05-11
- Volume
- 101
- Issue
- 23
- Pages
- 8756-8761
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC423268
- OpenAlex
- W2087723063
- Cited by
- 230
- References
- 36
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 6 · 2017: 8 · 2016: 5 · 2015: 5 · 2014: 13 · 2013: 9 · 2012: 10
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (DA3801, DA-3412, R01DA003801, K05DA000493, R01DA012447, DA09185, Z01DA000493, DA12447, R37DA003801)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- anandamide, fatty acid amide hydrolase, AM404, passive diffusion, endocannabinoid system, CB1 receptor, rimonabant, hypothermic effect, cortical neurons, astrocytes
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Arachidonic Acids, Benzamides, Biological Transport, Active, Cell Line, Humans, Hydrolysis, Mice, Inbred C57BL, Neurons, Rats, Wistar, Mice, Knockout, Mice, Rats, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.